Highlights from Innate Pharma's R&D update
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, today holds an R&D...
Programs & products
Start of cohort expansion of Phase I clinical trial testing the combination of lirilumab and nivolumab in selected solid tumors
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, today announced the...
Innate Pharma continues Phase II trial with lirilumab as planned, following Data and Safety Monitoring Board recommendation
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the Data...
Innate Pharma acquires full rights to ANTI-NKG2A checkpoint inhibitor from Novo Nordisk A/S
Novo Nordisk to reinforce its equity stake in Innate Pharma Marseille, France and Bagsværd, Denmark, 5 February 2014 Anti-NKG2A is a first-in-class therapeutic mAb that is Phase II ready NKG2A is a NK...
Innate Pharma initiates IPH43 program to develop «first-in-class» anti-MICA antibody
MICA validated as a novel target for antibody drug development in solid tumors IPH43 program now aims at selection and optimization of the best development candidate Innate Pharma SA (the “Company” -...
Preclinical data opening new perspectives for development of lirilumab in combination to be presented at ASH
Evidence for lirilumab single-agent activity in lymphoma Demonstration of enhanced efficacy of anti-CD20 antibodies when combined with lirilumab To be presented at ASH meeting, December 9, abstract...
Three posters on the anti-KIR program to be presented at the upcoming ASH annual meeting
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces today that three posters on...
Launch of IND-Enabling studies for IPH4102
IPH4102 is a first-in-class drug candidate targeting KIR3DL2, a receptor specifically expressed by some rare forms of cancer It is developed in an orphan disease, cutaneous T-cell lymphomas, and...
Innate Pharma announces first DSMB review of ongoing EffiKIR Phase II trial with lirilumab
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the Data...
Innate Pharma presents new data for proprietary programs targeting TLR3 and KIR3DL2
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces today that new preclinical data for...